Zoetis Inc., founded in 1952 and headquartered in Parsippany, New Jersey, is a leading global animal health company. The company's mission is to nurture the world by advancing animal care, which is vital for the comfort, companionship, and nutrition that people derive from animals. Zoetis develops, manufactures, and commercializes a wide range of animal health products, including medicines, vaccines, diagnostic products, parasiticides, and medicated feed additives. Their market focus spans both livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses).

Zoetis has achieved significant milestones, with a revenue of $8.54 billion and a net income of $2.34 billion in 2023. The company is publicly traded on the NYSE under the ticker ZTS and is a component of the S&P 500. Under the leadership of CEO Kristin Peck and Chair Michael McCallister, Zoetis has grown its global presence with approximately 14,100 employees worldwide. The company's commitment to animal health has made a substantial impact on the industry, enhancing the well-being of animals and supporting the needs of their owners.